Intraoperative frozen sections of periprosthetic tissues performed well in predicting a diagnosis of culture-positive periprosthetic joint infection but had moderate accuracy in ruling out this diagnosis. Frozen section histopathology should therefore be considered a valuable part of the diagnostic work-up for patients undergoing revision arthroplasty, especially when the potential for infection remains after a thorough preoperative evaluation. The optimum diagnostic threshold (number of PMNs per high-power field) required to distinguish periprosthetic joint infection from aseptic failure could not be discerned from the included studies. There was no significant difference between the diagnostic accuracy of frozen section histopathology utilizing the most common thresholds of five or ten PMNs per high-power field.
We describe a thymidine-dependent small-colony variant of Staphylococcus aureus associated with left ventricular assist device infection and prosthetic valve and pacemaker endocarditis. CASE REPORTT he patient was a 34-year-old woman who 3 years prior had suffered an anterior wall myocardial infarction resulting in ischemic cardiomyopathy, which necessitated placement of a pacemaker biventricular defibrillator. Subsequently, there was progressive deterioration of cardiac function. A left ventricular assist device (LVAD) was placed as a bridge to heart transplantation. During the same surgery, her native tricuspid valve was replaced with a pericardial tissue valve on account of tricuspid regurgitation. One month after surgery, she developed fever and chills, and blood cultures grew methicillin-resistant Staphylococcus aureus (MRSA) which was susceptible to gentamicin, rifampin, linezolid, trimethoprim-sulfamethoxazole (TMP-SMX), and vancomycin (MIC, 2 g/ml) and resistant to erythromycin and levofloxacin. Trans-esophageal echocardiography (TEE) showed no evidence of endocarditis. She was treated with 6 weeks of vancomycin and rifampin, with gentamicin administered during the first 2 weeks of therapy. Five days after completing antimicrobial therapy, she developed recurrent fevers, and blood cultures again grew MRSA which was susceptible to gentamicin, linezolid, TMP-SMX, vancomycin (MIC, 1 g/ml), and daptomycin and resistant to rifampin, erythromycin, and levofloxacin. A TEE demonstrated vegetations on the pacemaker leads and the prosthetic tricuspid valve. She was treated with daptomycin, gentamicin, and (until the isolate was known to be resistant to rifampin) rifampin. A follow-up TEE after 2 months of antimicrobial therapy showed reduction in the size of the vegetations. She received 5 months of daptomycin and gentamicin; TEE at the end of therapy showed old and healed vegetations. However, over the ensuing year, she had recurrent MRSA bacteremia and soft tissue infection surrounding her LVAD generator site. As a result, from December 2008 through March 2010, she received continuous antimicrobial therapy with various combinations of vancomycin, rifampin, daptomycin, gentamicin, quinupristin-dalfopristin, and TMP-SMX (Fig. 1). During this time, only one isolate (of several) was identifiable, and susceptibility testing was reportable using the BD Phoenix automated microbiology system (BD Diagnostic Systems, Franklin Lakes, NJ). That isolate, recovered from an umbilical driveline aspirate, was reported as susceptible to gentamicin, linezolid, TMP-SMX, and vancomycin (MIC, 2 g/ml), resistant to rifampin, erythromycin, and levofloxacin, and nonsusceptible to daptomycin (MIC, 4 g/ml). Because of inadequate growth in the test medium, other isolates, including bloodstream isolates and another umbilical driveline aspirate, were not identifiable, and susceptibility testing was not reportable using the BD Phoenix automated microbiology system.Despite ongoing combination antimicrobial therapy and incision and drainage of ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.